Last edition
News about "Gunilla Osswald"
US FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer's Disease
The US Food and Drug Administration (FDA) has approved Leqembi Iqlik (lecanemab-irmb) as a once-weekly subcutaneous starting dose for early Alzheimer's Disease (AD), with a U.S. launch planned for August 2026.
Gunilla Osswald | 14/07/2026 | By News Bureau
BioArctic and Lilly Sign Collaboration and Research Agreement for BrainTransporter-Based Therapy
BioArctic and Lilly have entered a research and collaboration agreement to combine a Lilly compound with BioArctic’s BrainTransporter technology. BioArctic will receive a USD 30 million upfront payment under the deal.
Gunilla Osswald | 24/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy